Navigation Links
Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients

WASHINGTON, May 21, 2007/PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced new data from study ETV-079, which showed that treatment with Baraclude (entecavir) demonstrated greater viral load reduction than adefovir at 48 weeks -- a result that was also seen at weeks 12 (primary endpoint) and 24. These data from an open-label, randomized viral kinetics study of 69 antiviral-naive chronic hepatitis B e-antigen (HBeAg) positive patients were presented at the annual Digestive Disease Week(R) meeting.

Study ETV-079 evaluated the antiviral activity of BARACLUDE and adefovir, and enrolled patients who had a high viral load at study entry (HBV DNA greater than or equal to 10(8) copies/mL). In this study, 58 percent of BARACLUDE-treated patients and 19 percent of adefovir-treated patients achieved undetectable viral load at 48 weeks.

"The study results show that BARACLUDE produced greater viral load reductions than adefovir at all time points analyzed -- from the earliest at 12 weeks to this latest analysis at 48 weeks," said Nancy Leung, M.D., of the Alice Ho Miu Ling Nethersole Hospital, Hong Kong, China.

The safety profile was comparable between the treatment groups. One patient treated with adefovir discontinued due to adverse events. No deaths were observed in either treatment group. The most common adverse events occurring in greater than 10 percent of patients in either treatment group were back pain, headache, influenza, nasopharyngitis, fever, upper respiratory tract infection, and urinary tract infection.

About the Study

Study ETV-079 was a randomized, open-label, comparative viral kinetics study of antiviral-naive chronic HBeAg-positive patients evaluating antiviral activity as measured by mean reduction in viral load, or levels of hepatitis B virus (HBV DNA) in the blood. HBeAg or e-antigen, is a viral protein associated with hepatitis B infe
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Baraclude (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment
2. Point of Care Strep Tests Speed Treatment, Lower Costs
3. Rapid HIV Testing Increases Possibility of Treatment
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
9. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:5/22/2015)... , May 22, 2015 Today, ... central nervous system stimulant indicated for the treatment ... patients beginning Summer 2015. The ... received approval from the U.S. Food and Drug ... an extended-release formulation of methylphenidate capsule with an ...
(Date:5/22/2015)... May 22, 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for the ... interim chief executive officer Howie Rosen will ... financial officer Tim Morris will be presenting ... two presentations are as follows: Jefferies 2015 ...
(Date:5/21/2015)... , May 21, 2015  When Ryan ... the side of his neck, he figured ... a couple weeks off from weight lifting. ... away.                               A series ... was referred to Michel Kliot, MD ...
Breaking Medicine Technology:Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4
... Company, Limited (hereafter, Daiichi Sankyo), announced today that the ... (JAN: Edoxaban Tosilate Hydrate, INN:edoxaban) 15 mg and 30 ... Welfare in Japan. Edoxaban, which is being ... anticoagulant that specifically, reversibly and directly inhibits the enzyme, ...
... Ontario, April 21, 2011 Valeant Pharmaceuticals International, Inc. ... the following statement to shareholders of Cephalon, Inc. (NASDAQ: ... today, the Cephalon Board of Directors stated that it ... Company,s alternatives and options – and is focused on ...
Cached Medicine Technology:Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery 2Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery 3Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery 4Valeant Pharmaceuticals Responds to Cephalon Board's Letter 2Valeant Pharmaceuticals Responds to Cephalon Board's Letter 3Valeant Pharmaceuticals Responds to Cephalon Board's Letter 4
(Date:5/22/2015)... 2015 A Phase 3 French ... Society of Clinical Oncology (ASCO)’s annual meeting at ... for those patients who received bevacizumab in addition ... Bevacizumab (Avastin® Genentech, Inc.) is an antibody that ... already routinely used to treat many other cancers, ...
(Date:5/22/2015)... 2015 In an effort to support ... is offering to donate $5 dollars for every maintenance ... or water softening system. Customers have their needs serviced, ... gets business; and the Special Olympics receives money. Hence ... helps over 4.4 million athletes, and boasts a myriad ...
(Date:5/22/2015)... 2015 A new program for the ... the field of Physical Therapy. , James Earl ... mystery out of physical therapy and discusses how the ... for a variety of ailments and injuries. Physical ... exercise plan that enhances daily activities such as house ...
(Date:5/22/2015)... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... religious leaders to make changes in order to achieve peace ... discusses the history of war, how it started, why it ... mankind was created to lead peaceful, joyful lives, very much ... “Yahweh created mankind, according to His Plan, which is still ...
(Date:5/21/2015)... York, New York (PRWEB) May 21, 2015 ... distributor of patented products, launches the Troll Motor Guide, ... convenient way of boating. , "The recreational boating industry ... Scott J. Cooper, CEO and Creative Director of ... water in record numbers and predicts continued steady growth ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:Parker and Sons is Proud to Support the Special Olympics with Their Everybody Wins Program 2Health News:Yisrayl Hawkins Calls on All Religions to Wake Up and Make Drastic Changes to End Suffering in New Letter 2Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 2Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 3
... of Vermont will elevate the state to being the second ... health-care insurance// , which will cover nearly 96 percent of ... definitely relief for the 46 million Americans who are not ... and costs of insurance premium showing an upward trend, this ...
... getting dirtier despite promises, claimed patients in a survey despite ... ,The annual NHS patients survey has found high levels of ... questions were asked of the 80,000 people who took part ... ward ha been ‘very clean’ as compared to 56% in ...
... Scotland's health minister Andy Kerr said that the NHS staff ... latest statistics on NHS waiting times// as the "best ever". ... had reduced from 12 to 6 months. ,Reports ... number of outpatients and inpatient day cases with an 18-week ...
... cases of diarrhoea in Ranchi, the Jharkhand Health department ... with the disease. // ,'We have equipped ... free-of-cost treatment to patients,' Health and Family Welfare's joint ... patients to avail free treatment at the hospital instead ...
... world , including India, must face the challenges of ... their citizens get access to effective healthcare // , ... medical expenses, a new World Bank report said. ... to cope with sharply rising costs even while countries ...
... by the Indian Medical Association, the junior doctors of ... colleges today struck work launching a one-day strike. ... and government dental hospitals were 'totally shut down', emergency ... Assoication, BMC told PTI., ,'We will watch the ...
Cached Medicine News:Health News:Quality Of NHS Hospitals Getting Dirtier Despite Promises 2Health News:Health Minister Praises Efforts By NHS In Reducing Patient Waiting Time 2Health News:Health Minister Praises Efforts By NHS In Reducing Patient Waiting Time 3
An enzyme linked immunoassay (ELISA) for the detection and semiquantitationof IgG and IgM antibodies to 2-GP1, as an aid in assessingthe risk of thrombosis in patients with Systemic Lupus Erythematos...
An enzyme linked immunoassay (ELISA) for the detection and semiquantitation of IgG, IgA or IgM anticardiolipin antibodies, as an aid in assessing the risk of thrombosis in individuals with Systemic L...
The ImagingPlanet 70 mm surgical microscope video adapter: superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Zeiss surgical...
The ImagingPlanet 55 mm surgical microscope video adapter: superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Leica surgical ...
Medicine Products: